Literature DB >> 4211992

Evaluation in nonhuman primates: evaluation of the physical dependence capacities of oripavine-thebaine partial agonists in patas monkeys.

A Cowan.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4211992

Source DB:  PubMed          Journal:  Adv Biochem Psychopharmacol        ISSN: 0065-2229


× No keyword cloud information.
  8 in total

1.  Behavioural effects of naloxone in rats.

Authors:  A Bertolini; S Genedani; M Castelli
Journal:  Experientia       Date:  1978-06-15

2.  Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal.

Authors:  Carol A Paronis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2010-11-04       Impact factor: 4.030

3.  Mixed agonist-antagonist opiates and physical dependence.

Authors:  J J Jacob; G M Michaud; E C Tremblay
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

Review 4.  Buprenorphine: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-02       Impact factor: 9.546

5.  Discriminative stimulus properties of naloxone.

Authors:  R B Carter; J D Leander
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

6.  Diprenorphine and naloxone in squirrel monkeys with enhanced sensitivity to opioid antagonists.

Authors:  A H Oliveto; L A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

7.  Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.

Authors:  A Cowan; J W Lewis; I R Macfarlane
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

8.  In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential.

Authors:  Taline V Khroyan; Andrea Cippitelli; Nicholas Toll; John A Lawson; William Crossman; Willma E Polgar; Lawrence Toll
Journal:  Front Psychiatry       Date:  2017-04-12       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.